ClinicalTrials.gg
CompletedNCT03489421(MITO+)Updated Sep 26, 2019

Mitochondria in HIV and Aging (MITO+)

An observational study in Human Immunodeficiency Virus (HIV) and Mitochondrial Diseases, sponsored by University of Colorado, Denver. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-09-26.

Primary conditionMitochondrial DiseasesRegistry: Acquired Immunodeficiency SyndromeReclassifiedWhy we changed it
Registry
Acquired Immunodeficiency Syndrome — the first condition term the registry derived for this study.
ClinicalTrials.gg
Mitochondrial Diseases
Why
  1. The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name Mitochondrial Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Colorado, Denver · Observational

Study type
Observational
Model
Case-control
Time perspective
Other
Enrollment
14
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 83 studies in Mitochondrial Diseases with a site in United States — 20 open to participants now, 22 under way, 3 of them phase 3. Mitochondrial Diseases · United States.

Enrollment
27th of 31
14 · median 61
Started
2018
with 6 others
Observational
31 of 83
10 open now
Registered
53rd of 83
by date

Among the 83 studies in Mitochondrial Diseases with a site in United States, this one is the 27th largest by enrollment of the 31 observational ones that give a count, is one of 7 that started in 2018, is one of 31 observational ones, and was the 53rd registered.

Mitochondrial Diseases

189 studies on the registry are indexed under Mitochondrial Diseases; 60 are open to participants now.

Browse Mitochondrial Diseases studies →

Open to participants now

20 of the 83 studies in Mitochondrial Diseases with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Mitochondrial Diseases studies recruiting now, 20 (50%) set no upper age limit and 13 (33%) stop at 75 or younger; 19 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Mitochondrial Diseases with a site in United States, or all of them as a file.
02

Study summary

Older adults with human immunodeficiency virus (HIV) and a long history of antiretroviral therapy have more mitochondrial dysfunction- the cells that help them make energy. This dysfunction in mitochondria may lead to symptoms of muscle fatigue, physical function impairment, and impaired exercise tolerance compared to HIV-uninfected controls of a similar age and body mass index (BMI). Furthermore, the investigators hypothesize that the older antiretroviral therapy (ART) of tenofovir disoproxil fumarate (TDF) is associated with greater impairment in mitochondrial function than the newer agent, tenofovir alafenamide (TAF).

03

Conditions studied

  • Human Immunodeficiency Virus (HIV)
  • Mitochondrial Diseases

Browse trials for

04

In context

Mitochondrial Diseases Reclassified

189 studies on the registry are indexed under Mitochondrial Diseases; 60 are open to participants now.

This study's enrollment of 14 is below the median of 80 across 65 observational studies indexed under Mitochondrial Diseases.

Browse Mitochondrial Diseases studies →

Lead sponsor

University of Colorado, Denver is the lead sponsor of 1,543 studies on the registry; 317 are open to participants now.

Of its 147 completed or terminated interventional studies of FDA-regulated products, 92 (63%) have results posted.

Compared within Mitochondrial Diseases, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Acquired Immunodeficiency Syndrome. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

HIV-infected participants will be those living with HIV, between the ages of 50-75 years, recruited from the University of Colorado Infectious Diseases Group Practice HIV-uninfected participants were previous enrolled and completed an IRB approved protocol (historical database).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between the ages of 50-75 years at study entry (a subset of participants changing from TDF-based ART to TAF-based ART will also have mitochondrial function measured and the age range for this subset is 18-70)

    • Known infection or presumed HIV uninfected (will be confirmed at screening)
    • For HIV+ participants: must be on an ART regimen (change in regimen permitted for preference/tolerability but not for virologic failure) for a minimum of 5 years, with a viral load \< 200 during the prior 2 years. The investigators will initially target 10 years of therapy, but will expand to 5 years if needed for enrollment.
    • Although any ART regimen will be allowed if effective (as above), the investigators will first target participants that have a history of > 5 years of TDF exposure and are currently on TAF or TDF, but no prior exposure to AZT or stavudine.
    • greater than 200 cells/mm3
    • All participants must be able to perform activities of daily living without assistance, and ambulate independently.
    • Sedentary as defined above
    • as defined by cessation of menstrual periods for at least 12 months without any other obvious pathological or physiological cause OR removal of ovaries at least 12 months prior to enrollment.
    • between 25-38 kg/m2

Exclusion criteria

  • Participation in another clinical trial where the therapy is unknown or blinded.

    • Diabetes, as defined by use of diabetes medications, 6.5 or greater, fasting plasma glucose 126 mg/dL or greater, or random plasma glucose 200 mg/dL or greater.
    • Persons on statin therapy (as possible; this criteria may be removed for recruitment difficulties).
    • Fasting triglycerides > 400
    • Untreated or incompletely treated thyroid disease will be excluded; stable therapy for > 6 months will be allowed.
    • Persons on growth hormone or growth hormone axis therapy (i.e., tesamorelin) will be excluded.
    • The investigators will initially target men, women, or transgendered individuals without replacement hormone use. If the investigators are unable to recruit the target number of participants, stable (>3 months) estrogen or testosterone within physiologic replacement dose range will be permitted.
    • use, including intra-articular, will be excluded (within 3 months for oral; within 6 months for intra-articular); inhaled or intranasal will be permitted.
    • medications within 6 months, including methotrexate, infliximab, azathioprine, etc.
    • Women that are pregnant, breast-feeding, or intend to become pregnant.
    • Known or C with detectable viremia within in the past 6 months.
    • with undetectable viral load for at least 6 months will be allowed.
    • Known mitochondrial disorder
    • Severe liver disease other than hepatitis B or C due to interference with systemic cytokine production
    • Uncontrolled hypertension defined as resting systolic blood pressure (BP) >180 mmHg or diastolic BP >100 mmHg
    • Indicators of unstable ischemic heart disease
    • Class III or IV congestive heart failure, aortic stenosis, uncontrolled angina, or uncontrolled arrhythmia
    • Pulmonary disease requiring the use of supplemental oxygen
    • Active (excluding non-melanoma skin cancers) within 24 weeks prior to enrollment
    • Surgery/trauma/injury/fracture within 12 weeks prior to enrollment that may limit ability to perform physical function testing.
    • Acute infection (skin infection, sinus infection, uncomplicated upper respiratory infection, dental infection, etc) within 2 weeks of study entry will be excluded until the infection has resolved for at least 2 weeks
    • Chronic, deeper infections (complicated pneumonia, bone infection, liver abscess, deep wound infection, etc) must have completed treatment and show no evidence of ongoing infection for at least 12 weeks
    • History of stroke with residual deficits
    • Any medical condition that does not allow for a non-contrasted MRI study (ie, pacemaker, shrapnel, other devices or hardware)
    • AIDS-defining opportunistic infection75 within the 24 weeks prior to enrollment
    • Severe anemia, defined as a of 9 mg/dL or less
    • Participants on anticoagulants (clopidogrel, Coumadin, etc). Patients on short-acting anticoagulant therapy requiring dose cessation for only 48-72 hours can be considered for muscle with approval by their treating physician.
    • Aspirin and Non-steroidal anti-inflammatory agents are not exclusions but should be stopped 1 week prior to biopsy.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

06

Study design

Observational model
Case-control
Time perspective
Other
Enrollment
14 participants (actual)
Patient registry
No

Groups and cohorts

  • HIV Infected
  • Un-infected controls

    Controls without HIV from a historical pre-approved-IRB-protocol database

07

What researchers measure

Primary outcomes

  1. ADP/ATP measurement (mitochondrial function)

    ADP/ATP ratio between HIV-infected and uninfected subjects

    Time frame: At Baseline

Secondary outcomes

  1. Protein citrate synthase

    Total protein citrate synthase between HIV-infected and seronegative subjects

    Time frame: At Baseline

  2. Respiratory control ratio (RCR)

    Respiratory control ratio (RCR) between HIV-infected and uninfected subjects

    Time frame: At Baseline

  3. Inflammatory markers

    Relationship between markers of inflammation (final panel to be determined, but most likely sTNFR1 and 2 in addition to multiplex panel of IL-6, IL-10, CRP, IFN-G) and their effect on mitochondrial function

    Time frame: At Baseline

  4. Muscle function

    Relationship between measures of muscle function (strength, physical function) and mitochondrial function

    Time frame: At Baseline

  5. TDF to TAF change

    A separate group of participants changing from TDF-based ART to TAF-based ART will also have mitochondrial function measures before and after change. The inclusion criteria are similar except the age range is 18-70.

    Time frame: At Baseline

08

Study locations

1 site
  • University of Colorado - Anschutz Medical Campus
    Aurora, Colorado 80045, United States
09

References and documents

Individual participant data

Plan to share: No — IPD is kept private per UC Denver restrictions

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Sep 2019, 8 months.

Of 33 observational studies under Mitochondrial Diseases, half reached primary completion within 169 months of starting (the median), counting those still running; a quarter within 26. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2018
First posted
Apr 5, 2018
StartActual
Dec 15, 2018
Primary completionActual
Sep 5, 2019
CompletionActual
Sep 5, 2019
Last update
Sep 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03489421
Responsible party
Sponsor
First posted
Apr 5, 2018
Start date
Dec 15, 2018
Primary completion
Sep 5, 2019
Completion
Sep 5, 2019
Last update
Sep 26, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion